Trypanosomatid parasites cause diseases like African sleeping sickness, Chagas’ disease and leishmaniasis. Leishmaniasis affects about 12 million people worldwide, mostly in developing countries. Current drug treatments are inadequate due to drug toxicity and resistance.
Now, a group of European scientists has discovered new compounds that may help to fight these diseases more effectively. The project was carried out by research groups headed by Maria Paola Costi (University of Modena and Reggio Emilia, Italy), Rebecca Wade (HITS, Heidelberg Institute for Theoretical Studies, Germany) and Paul Michels (De Duve Institute , Belgium). It was supported by the Cassa di Risparmio di Modena Foundation. The research results have been published in the Journal of Medicinal Chemistry.
Trypanosomatids require folates and biopterins. These are reduced by the enzymes dihydrofolate reductase (DHFR) and pteridine reductase (PTR1). When DHFR is inhibited, DNA replication is impaired, resulting in cell death. However in trypanosomatids, PTR1 is overexpressed when DHFR is inhibited, and PTR1 can take on the role of DHFR by reducing folates, ensuring parasite survival. For the treatment of anti-parasitic diseases, it is thus necessary to block two metabolic pathways by simultaneously inhibiting DHFR and PTR1 by a single drug or a combination of two specific inhibitors. PTR1 is not present in humans and is thus an excellent target for the design of specific compounds that target the parasite.
In this project, the scientists used a virtual screening approach combined with experimental screening methodologies, to identify non-folate-like inhibitors of Leishmania PTR1. Optimization was performed in two rounds of structure-based drug design cycles to improve specificity for PTR1 and selectivity against human DHFR, resulting in 18 drug-like molecules with low micromolar affinities and high in-vitro specificity profiles. Assays of efficacy in cultured Leishmania cells showed six compounds that were active in combination with a DHFR inhibitor. One of these was also effective alone. Several of these compounds showed low toxicity profiles, and one of them is a known drug approved for treatment of diseases of the central nervous system, suggesting potential for label extension of this compound as an anti-parasitic drug candidate.The original scientific article:
http://www.unimore.itHITS (Heidelberg Institute for Theoretical Studies)
http://www.h-its.orgDe Duve Institute, Université catholique de Louvain
Dr. Peter Saueressig | idw
Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München
Second research flight into zero gravity
21.10.2016 | Universität Zürich
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences